Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02068326
Other study ID # SJ-371
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2015
Est. completion date April 11, 2019

Study information

Verified date June 2020
Source Psychiatric Research Unit, Region Zealand, Denmark
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: Although it is now possible to diagnose Borderline Personality Disorder (BPD) in adolescents younger than 18 years according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V), and studies indicates that BPD can be reliably diagnosed in adolescence, only a few evidence based treatment programmes for adolescent BPD exists. Mentalization-based treatment (MBT), including group psychotherapy, has repeatedly shown to be effective in treating adult BPD, but in the case of adolescents, only individual MBT have been tested and found to be effective.

Aims/hypotheses: We will test whether group based MBT (MBT-G), including an introductory programme for patients (MBT-I) and their parents (MBT-P) is more effective than Treatment As Usual (TAU) in treating adolescents with BPD or subthreshold BPD.

Methods/Design: 112 patients referred to child and adolescent psychiatric clinics in Region Zealand will be randomized to either MBT or TAU. Inclusion criteria: Meeting DSM-V BPD-criteria at the threshold (five criteria) or sub threshold level (4 criteria). Follow-up will be at three and 12 months.

Discussion: Early intervention is especially important in relation to personality psychopathology and has long-term benefits for patients, their families and society. In addition to being cost effective, using the group modality in the treatment of BPD may have several advantages. This is the first Randomized Controlled Trial (RCT) to test the effectiveness of MBT in groups for adolescents.


Recruitment information / eligibility

Status Completed
Enrollment 112
Est. completion date April 11, 2019
Est. primary completion date May 11, 2018
Accepts healthy volunteers No
Gender All
Age group 14 Years to 17 Years
Eligibility Inclusion Criteria:

- Meet a minimum of 4 DSM-5 BPD criteria

- Have parent's or parent substitute's commitment and ability to participate in the MBT-Parents program.

- Score 67< BPFS-C

Exclusion Criteria:

- Comorbid diagnosis of pervasive developmental disorder, learning disability (75 < IQ), anorexia, current psychosis, diagnosis of schizophrenia or schizotypal personality disorder, antisocial personality disorder as well as any other axis-I or axis-II psychopathology considered to be the primary diagnosis.

- Current psychiatric inpatient treatment

- Current (past two months) substance dependence (but not substance misuse)

- Participation in concurrent psychotherapeutic treatment outside the MBT program

- Not able to speak Danish

- Lack of informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Mentalization Based Treatment

Treatment As Usual
Treatment As Usual

Locations

Country Name City State
Denmark Child and Adolescent Psychiatric Department, Region Zealand Roskilde Region Zealand

Sponsors (1)

Lead Sponsor Collaborator
Psychiatric Research Unit, Region Zealand, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Experience of Close Relationships Inventory (ECR) Treatment related variable (mediator) Change from baseline at 40 weeks
Other Experience of Close Relationships Inventory (ECR) Treatment related variable (mediator) Change from baseline at 10 weeks
Other Experience of Close Relationships Inventory (ECR) Treatment related variable (mediator) Change from baseline at 20 weeks
Other Experience of Close Relationships Inventory (ECR) Treatment related variable (mediator) Change from baseline at 30 weeks
Other Inventory of Parent and Peer Attachment - Revised (IPPA-R) Treatment related variable (mediator) Change from baseline at 40 weeks
Other Inventory of Parent and Peer Attachment - Revised (IPPA-R) Treatment related variable (mediator) Change from baseline at 10 weeks
Other Inventory of Parent and Peer Attachment - Revised (IPPA-R) Treatment related variable (mediator) Change from baseline at 20 weeks
Other Inventory of Parent and Peer Attachment - Revised (IPPA-R) Treatment related variable (mediator) Change from baseline at 30 weeks
Other Reflective Function Questionnaire for Youth (RFQ-Y) Treatment related variable (mediator) Change from baseline at 40 weeks
Other Reflective Function Questionnaire for Youth (RFQ-Y) Treatment related variable (mediator) Change from baseline at 10 weeks
Other Reflective Function Questionnaire for Youth (RFQ-Y) Treatment related variable (mediator) Change from baseline 20 weeks
Other Reflective Function Questionnaire for Youth (RFQ-Y) Treatment related variable (mediator) Change from baseline at 30 weeks
Primary The Borderline Personality Feature Scale for Children (BPFS-C) Change from Baseline in BPFS-C at 40 weeks
Primary The Borderline Personality Feature Scale for Children (BPFS-C) Change from Baseline in BPFS-C at 10 weeks
Primary The Borderline Personality Feature Scale for Children (BPFS-C) Change from baseline at 20 weeks
Primary The Borderline Personality Feature Scale for Children (BPFS-C) Change from baseline at 30 weeks
Secondary Becks Depression Inventory for Youth Change from Baseline in at 10 weeks
Secondary Becks Depression Inventory for Youth Change from Baseline in at 20 weeks
Secondary Becks Depression Inventory for Youth Change from Baseline in at 30 weeks
Secondary Becks Depression Inventory for Youth Change from Baseline in at 40 weeks
Secondary The Risk-Taking and Self-Harm Inventory for adolescents (RTSHIA) Change from baseline at 40 weeks
Secondary The Risk-Taking and Self-Harm Inventory for adolescents (RTSHIA) change from baseline at 10 weeks
Secondary The Risk-Taking and Self-Harm Inventory for adolescents (RTSHIA) change from baseline at 20 weeks
Secondary The Risk-Taking and Self-Harm Inventory for adolescents (RTSHIA) Chage from baseline at 30 weeks
Secondary ZAN-BPD Zanarini Rating Scale for Borderline Personality Disorder Change from baseline at 40 weeks
Secondary The Health of the Nation Outcome Scale for Children and Adolescent (HoNOSCA) Change from baseline at 40 weeks
Secondary The Childrens' Global Assessment Scale (CGAS) Change from baseline at 40 weeks
Secondary The childhood behaviour checklist (CBCL, Parental outcome measure) Change from baseline at 40 weeks
Secondary The childhood behaviour checklist (CBCL, Parental outcome measure) Change from baseline at 10 weeks
Secondary The childhood behaviour checklist (CBCL, Parental outcome measure) Change from baseline at 20 weeks
Secondary The childhood behaviour checklist (CBCL, Parental outcome measure) Change from baseline at 30 weeks
Secondary The borderline personality feature scale for Children - parental version (BPFS-P) Change from baseline at 40 weeks
Secondary The borderline personality feature scale for Children - parental version (BPFS-P) Change from baseline at 10 weeks
Secondary The borderline personality feature scale for Children - parental version (BPFS-P) Change from baseline at 20 weeks
Secondary The borderline personality feature scale for Children - parental version (BPFS-P) Change from baseline at 30 weeks
Secondary Number of patients' hospital admissions and visits to the emergency room Change from baseline at 40 weeks
Secondary The Youth Self-Report (YSR) Change from baseline at 10 weeks
Secondary The Youth Self-Report (YSR) Change from baseline at 20 weeks
Secondary The Youth Self-Report (YSR) Change from baseline at 30 weeks
Secondary The Youth Self-Report (YSR) Change from baseline at 40 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04856449 - DBT Skills Plus EMDR for BPD and Trauma N/A
Active, not recruiting NCT04587518 - Five Factor Model Treatment for Borderline Personality Disorder N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Completed NCT03677037 - The Short-Term MBT Project Phase 3
Not yet recruiting NCT05989529 - Delving Into Borderline Personality Disorder Clinical Trial Experiences
Completed NCT02518906 - Evaluation of AIT Study N/A
Recruiting NCT04296604 - Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations N/A
Terminated NCT02149823 - Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Phase 1
Completed NCT02108990 - Acetaminophen and Social Processes Phase 2
Completed NCT01635556 - Evaluation of a Modified Dialectical Behavior Therapy Program N/A
Not yet recruiting NCT01683136 - Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Feasibility Study for the Treatment of Borderline Personality Disorder N/A
Completed NCT02988037 - Adapted Dialectical Behaviour Therapy for Adolescents With Deliberate Self-Harm: A Pre-post Observational Study N/A
Completed NCT02397031 - Mindfulness and Interpersonal Effectiveness Skills in Borderline Personality Disorder N/A
Terminated NCT01212588 - Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD) Phase 2
Terminated NCT01103180 - Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder Phase 2
Terminated NCT00539188 - N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD Phase 2
Recruiting NCT05398627 - Neurofeedback for Borderline Personality Disorder N/A
Recruiting NCT03994510 - SHame prOpensity in bOrderline Personality Disorder N/A
Recruiting NCT06005129 - Personality Change Study for Borderline Personality Disorder N/A
Recruiting NCT06106555 - Which Factors Are Relevant for Treatment Outcome in Dialectical Behaviour Therapy for Borderline Personality Disorder?